A$24.6 million for Australian clinical trials hub on regional cancer trials

25 March 2019
australia-big

The Australian government is providing almost A$25 million ($17.8 million) so Australians with cancer and rare diseases have access to clinical trials no matter where they live including regional and remote Victoria.

Patients with poor access to clinical trial programs don’t always gain early access to breakthroughs in medical treatment that can be life-saving. The government will provide funding support to the Australian Clinical Trials Network’s TrialHub.

This will boost opportunities for patients across Australia to participate in clinical trials of new treatments and other interventions as close as possible to their homes, regardless of where they live.

The program will create partnerships with regional hospitals to expand the reach and participation in clinical trials, allowing patients from all over Victoria access to potentially life-saving treatments. TrialHub’s initial focus will be on rare cancers and other rare diseases, prostate cancer and melanoma.

This program is a collaboration between Monash University and Alfred Health to boost the number of available clinical trials in Victoria.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical